Danaher Corporation
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Danaher Corporation (DHR). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Diagnostics | – | – | – | $9.58B 40.1% | $9.79B 41.0% · +2.2% | $9.94B 40.5% · +1.6% |
| Life Sciences | – | – | – | $7.14B 29.9% | $7.33B 30.7% · +2.6% | $7.33B 29.9% · +0.1% |
| Biotechnology | – | – | – | $7.17B 30.0% | $6.76B 28.3% · -5.8% | $7.29B 29.7% · +7.9% |
| Biotechnology | $5.28B 23.7% | $8.57B 34.6% · +62.4% | $8.76B 32.9% · +2.2% | – | – | – |
| Life Sciences | $5.30B 23.8% | $6.39B 25.8% · +20.5% | $7.04B 26.4% · +10.1% | – | – | – |
| Diagnostics | $7.40B 33.2% | $9.84B 39.7% · +33.0% | $10.85B 40.7% · +10.2% | – | – | – |
| Environmental & Applied Solutions | $4.31B 19.3% | – | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Diagnostics | – | – | – | $2.41B 25.1% | $2.63B 26.8% | $2.65B 26.7% |
| Life Sciences | – | – | – | $1.21B 16.9% | $879.0M 12.0% | $520.0M 7.1% |
| Biotechnology | – | – | – | $1.91B 26.6% | $1.69B 24.9% | $1.86B 25.6% |
| Biotechnology | $1.08B 20.5% | $3.07B 35.9% | $3.01B 34.3% | – | – | – |
| Life Sciences | $972.0M 18.3% | $1.29B 20.2% | $1.41B 20.1% | – | – | – |
| Diagnostics | $1.54B 20.8% | $2.31B 23.5% | $3.44B 31.7% | – | – | – |
| Environmental & Applied Solutions | $979.0M 22.7% | – | – | – | – | – |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| North America | $9.01B 40.4% | $9.80B 39.5% · +8.7% | $11.73B 44.0% · +19.7% | $9.96B 41.7% · -15.1% | $10.30B 43.1% · +3.4% | $10.36B 42.2% · +0.6% |
| High-growth markets | – | – | $7.71B 28.9% | $7.19B 30.1% · -6.7% | $6.87B 28.8% · -4.5% | $7.02B 28.6% · +2.2% |
| Western Europe | $5.32B 23.9% | $5.88B 23.7% · +10.4% | $5.86B 22.0% · -0.3% | $5.47B 22.9% · -6.7% | $5.46B 22.9% · -0.2% | $5.94B 24.2% · +8.8% |
| Other developed markets | – | – | $1.35B 5.0% | $1.27B 5.3% · -5.6% | $1.25B 5.2% · -1.3% | $1.25B 5.1% · -0.1% |
| Other developed markets | $1.30B 5.8% | $1.36B 5.5% · +4.5% | – | – | – | – |
| High-growth markets | $6.65B 29.8% | $7.77B 31.3% · +16.8% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Recurring | $19.14B 77.2% | $20.88B 78.4% · +9.1% | $18.68B 78.2% · -10.5% | $19.37B 81.1% · +3.7% | $20.13B 81.9% · +3.9% |
| Nonrecurring | $5.67B 22.8% | $5.77B 21.6% · +1.8% | $5.21B 21.8% · -9.7% | $4.51B 18.9% · -13.4% | $4.44B 18.1% · -1.5% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.